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26
Despite greater blood pressure reactivity to acute cardiovascular stressors and a higher 27 prevalence of hypertension in type 2 diabetes (T2D) patients, limited information is available 28 regarding arterial baroreflex (ABR) control in T2D. We hypothesized that ABR control of 29 muscle sympathetic nerve activity (MSNA) and heart rate (HR) are attenuated in T2D patients.
30
Seventeen T2D-patients (50±2 yrs; 31±1 kg/m 2 ), 9 weight-matched controls (WM-CON, 46±2 , P<0.05), and also tended to be reduced in WM-CON (9.3±1.9 ms·mmHg -39 1 ) compared to Lean-CON (P=0.059). Likewise, during BP rises, cardiac baroreflex gain was 40 reduced in T2D-patients and weight-matched controls compared to lean controls (P<0.05), 41 whereas no group differences were found during BP falls (P>0.05). Sympathetic and cardiac
42
ABR gains were comparable between normotensive and hypertensive T2D-patients (P>0.05).
43
These findings suggest preserved ABR control of MSNA in T2D-patients compared to both 44 obese and lean age-matched counterparts, with a selective impairment in ABR HR control in 45 T2D that may be related to obesity. 
New and Noteworthy
48
We show for the first time preserved arterial baroreflex control of sympathetic nerve 49 activity in type 2 diabetes patients with selective impairment in cardiac baroreflex control that 50 appears related to obesity. These findings lend important insight into blood pressure regulation in 51 a patient population prone to developing hypertension. Indeed, previous work has demonstrated differences in ABR function in humans when 75 examining falls vs. rises in BP separately that would have otherwise been missed when 76 examining the overall baroreflex gain alone (18, 26, 51) . Thus, it is clear that a comprehensive 77 assessment of ABR function is warranted in patients with T2D.
78
Given this background, we tested the hypothesis that T2D-patients exhibit reductions in 79 sympathetic and cardiac baroreflex gain compared to age, weight, and sex-matched control 80 subjects. Furthermore, since body weight-matched controls for the T2D-patients were obese, and 81 obesity has been shown to alter ABR function (3, 6, 21- hypotension and hypertension were also separately examined using the segments from the onset 171 of the diastolic BP fall after nitroprusside infusion until the nadir of the BP change, and from the 172 lowest diastolic BP after phenylephrine administration until the peak rise in BP, respectively.
173
Since poor linear regression modeling could increase the chances of committing a type II error, a 174 minimum R value of 0.5 was used for accepting the linear regressions. In this regard, linear 175 regressions could not be constructed for 1 T2D patient due to the lack of data points, and 2 T2D-176 patients did not reach R ≥ 0.5 for BP rises (phenylephrine), and 1 lean control did not reach R ≥ 177 0.5 for BP falls (sodium nitroprusside). All baroreflex trials were evaluated separately and the 178 multiple trials from each subject were averaged together to obtain a mean response for that 179 subject.
180
For spontaneous sympathetic baroreflex sensitivity, MSNA was averaged over 3-mmHg 181 diastolic BP bins during the baseline period, and the relationship between the spontaneous 182 changes in MSNA and diastolic BP was assessed using a weighted linear regression analysis. In 183 addition to total MSNA, burst incidence (percentage of heart beats associated with a burst of 184 MSNA) was also calculated for spontaneous sympathetic baroreflex sensitivity (27). Inc.) and statistical significance was set at P < 0.05.
243
Results
244
Subject Characteristics. As expected, body weight, and body mass index (BMI), were similar 245 among weight-matched controls and T2D-patients, but was lower in lean controls (P<0.05)
246
( patients, +17 ± 1; WM-CON, +21 ± 2; Lean-CON, +18 ± 2 mmHg; P>0.05). No significant 277 correlations were noted between sympathetic ABR gain and BMI, waist circumference, waist/hip 278 ratio or HbA1c (all P>0.05).
279
For spontaneous measures of sympathetic ABR sensitivity, no differences were observed 280 between any of the groups for the control of total MSNA (P>0.05, Figure 3D ). Likewise, 281 spontaneous sympathetic ABR sensitivity as determined by MSNA burst incidence was also Oxford are presented in Figure 2B . Overall cardiac ABR gain was not different between T2D-290 patients and weight-matched controls (P>0.05). Similarly, no significant group differences were 291 detected in cardiac ABR gain during BP falls (nitroprusside) or BP rises (phenylephrine).
292
However, overall cardiac ABR gain was significantly reduced in T2D-patients compared to lean 293 controls (P<0.05), and also tended to be reduced in weight-matched controls compared to Lean-294 CON (P=0.059, Figure 4A ). Likewise, during BP rises, cardiac ABR gain was reduced in 295 weight-matched controls and T2D-patients compared to lean controls (P<0.05), whereas no 296 group differences were found during BP falls (P>0.05) ( Figure 4B and C). When adjusting for 297 BMI (ANCOVA), no significant differences were found among groups for overall cardiac gain gain and waist circumference (R=-0.2) or waist/hip ratio (R=0.14) (both P>0.05).
310
Spontaneous cardiac ABR sensitivity was significantly reduced in T2D-patients and 311 weight-matched controls compared to lean controls (P<0.05), as well as cardiac ABR sensitivity 312 derived during BP falls and BP rises separately (both P<0.05 vs. Lean-CON) ( Figure 4D-F) .
313
Unlike the modified Oxford, the group differences observed in spontaneous cardiac ABR 314 sensitivity persisted when adjusting for BMI (P<0.05). Interestingly, the number of sequences 315 detected were significantly lower among lean controls compared to T2D-patients and weight- 
335
For cardiac ABR gain during the modified Oxford, no differences between T2D-patients 336 with and without hypertension were seen for overall gain, and for BP falls and rises (P>0.05; 337 Figure 5D -F). Similarly, no group differences were seen for any measure of spontaneous cardiac 338 ABR sensitivity (P>0.05).
340
Discussion
341
The primary novel findings of the present study are twofold: 1) ABR control of MSNA is 342 not reduced in the presence of T2D, and 2) ABR control of HR is impaired similarly among 343 T2D-patients and obese subjects compared to healthy lean subjects of the same age. These T2D-patients in the present study were taking anti-hyperglycemic medications (Table 1) In contrast to ABR-MSNA control, overall cardiac ABR gain was significantly reduced 374 in T2D-patients compared to lean controls. Likewise, during BP rises, cardiac ABR gain was 375 significantly reduced in T2D-patients as well as weight-matched controls in comparison to lean 376 controls. Since the T2D-patients and weight-matched controls were obese, and obesity has been 377 shown to reduce cardiac ABR function (3, 6), these findings were not surprising. Indeed, we 378 reasoned that ABR control of HR would be impaired in both T2D-patients and weight-matched 379 controls; however, we hypothesized that the presence of T2D would further impair ABR control 380 of HR. Yet, the magnitude of impairment in ABR control of HR that was observed was overall 381 quite similar between T2D-patients and weight-matched controls. These data suggest that the 382 impairment may be a result of the co-existence of obesity, which is supported by a lack of group 383 differences in cardiac ABR gain when taking BMI into account using a covariate analysis.
384
Although reductions in cardiac baroreflex gain with obesity are consistent with previous reports 385 (3, 6), it is not entirely clear why obesity would selectively impair ABR control of HR in the 386 present study, but not impair ABR control of MSNA. It is likely that reductions in cardio-vagal 387 tone/activity contribute to impaired ABR HR control with obesity. The importance of vagal 388 efferent activity in ABR control of HR is well documented and impairments in vagal activity to 389 the heart have been reported in obesity (31, 45). We also observed lower indices of cardio-vagal 390 tone in T2D-patients and obese controls compared to lean controls (Table 2) . These data suggest 391 that in the course of metabolic disease progression in obese subjects parasympathetic regulation 392 deficits may appear before the onset of sympathetic impairments. However, alterations in 393 parasympathetic activity may not be the only reason for selective cardiac baroreflex impairment 394 with obesity. Indeed, there is a growing body of research suggesting that descending neural 395 inputs from hypothalamic regions, as well as inputs from brainstem regions, can influence ABR 396 control of HR and MSNA independently (19, 36, 38, 42) . Likewise, the hypothalamus has been 397 implicated in both metabolic and autonomic nervous system disturbances in diet-induced animal 398 models of obesity and in human obesity (43, 55, 58) . Given previous work suggesting 399 preservation of the afferent arm of the ABR in obese animals (29), impairments in vagal efferent 400 activity or central nuclei may likely be involved and warrant future consideration.
401
T2D is often associated with hypertension (4, 50), which has previously been shown to 402 impair ABR function (7, 12, 35) . For this reason, we compared ABR function in T2D-patients with T2D have exaggerated increases in both MSNA and BP to acute stressors (27, (39) (40) (41) .
417
These data are clinically important given that greater cardiovascular reactivity increases the risk 418 for myocardial infarction and stroke among T2D patients (5, 32, 33, 59) . Moreover, such data are We thank Charla Jay, R.N., for assistance with screening blood draws and patient recruitment.
459
We also thank Joseph W. LeMaster, MD, Uzma Khan, MD, James P. Fisher 
